The Overactive Bladder Symptom Score, International Prostate Symptom Score–Storage Subscore, and Urgency Severity Score in Patients With Overactive Bladder and Hypersensitive Bladder: Which Scoring System is Best? / 대한배뇨장애요실금학회지

PURPOSE: To evaluate the correlations among the Overactive Bladder Symptom Score (OABSS), International Prostate Symptom Score–Storage Subscore (IPSS-S), and the modified Urgency Severity Scale (USS) in patients with overactive bladder (OAB) and hypersensitive bladder (HSB) and to identify the most useful diagnostic tool for classifying the severity of OAB. METHODS: We retrospectively reviewed the charts of consecutive patients with OAB who visited our urologic clinics for treatment. All patients underwent a detailed history, physical examination, urinalysis, uroflowmetry, and postvoid residual volume measurement, and completed a 3-day voiding diary. All patients answered the Chinese versions of the IPSS, OABSS, and USS, according to which they were classified as having wet or dry OAB based on whether their chief complaint was urgency urinary incontinence or urgency without incontinence. HSB was defined as a functional bladder capacity OABSS>IPSS-S. The simplest survey, the USS, with a single item scored from 0 to 4, had the strongest correlation with the OAB severity subgroups.

The efficacy of Thai capsaicin in the treatment of primary detrusor instability and hypersensitive bladder.

Our an objective was to study the efficacy of Capsaicin extracted from Capsaicin frutescen in treating the patients with hypersensitive bladder and primary detrusor instability. Eleven patients, 3 males and 8 females, with average age of 60.3ฑ14.3 years were treated by intravesical instillation 1 mM/L Capsaicin in 30% ethanol in an amount half of the bladder capacity for 30 minutes after instillation 2% xylocaine without adrenaline for 15 minutes three out of the 11 patients who could not tolerate the pain by this method were anesthesized with regional or general anesthesia. The results were as follow :- 1. Clinical symptoms were improved significantly, i e. the frequency was reduced from day : night = 19.45ฑ17.99 : 7.09ฑ6.30 to 12.00ฑ8.91 : 4.09ฑ3.8 at p < 0.05 and leakage almost disappeared. 2. Maximal bladder capacity increased from 197.45ฑ156.06 ml to 323.45ฑ129.46 ml which was statistically significant (p=0.009). 3. Detrusor pressure at maximal bladder capacity increased from 32.63ฑ22.76 cmH2O to 36.63ฑ19.21 cmH2O but was not statistically significant (P=0.823). 4. Voiding pressure nonsignificantly increased from 47.1ฑ6.4 cmH2O to 48.1ฑ6.6 cmH2O (p=0.959). The adverse effects found were burning pain at suprapubic area, sweating and hematuria.